Inhalte im Video:
Interview mit:
Interview von:
Produziert von:
ESMO 2019: Kopf-Hals-Tumore – EXTREME bei fitten Älteren, neue Wirkstoffe
Für Assoz.-Prof. PD Dr. Thorsten Füreder, Universitätsklinik für Innere Medizin, Wien, war das Highlight dieses ESMO die Studie zum XIAP-Inhibitor Debio. Mit Monalizumab gab es eine Enttäuschung.
Abstracts, die in diesem Video besprochen werden:
- Chen M et al. Chemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial. #1108O
- Juigay J et al. Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials. #1110O
- Bourhis J et al. Double-blind randomized phase II results comparing concurrent highdose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study. #LBA65
- Galot R et al. 1109O – A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
ESMO Congress 2019